Immunogenicity and Reactogenicity of a Single Dose of Live Attenuated Varicella Vaccine and a Booster Dose of Measles–Mumps–Rubella Vaccine Given Concomitantly at 12 years of Age

References

• Varughese PV Chickenpox in Canada, 1924–87. Can Med Assoc J 1988; 138: 133–4.
   Google Scholar
• Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infection. J Pediatr 1997; 130: 759–65.
   Google Scholar
• Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis 1984; 3: 505–9.
   Google Scholar
• Preblud SR. Varicella: complications and costs. Pediatrics 1986; 78: 728–35.
   PubMed Web of Science ®Google Scholar
• Preblud SR, Bergman DJ, Vernon LL. Deaths from varicella in infants. Pediatr Infect Dis 1985; 4: 503–7.
   PubMedGoogle Scholar
• Jaeggi A, Zurbruegg RP, Aebi C. Complications of varicella in a defined central European population. Arch Dis Child 1998; 79: 472–7.
   PubMed Web of Science ®Google Scholar
• Andre FE. Worldwide experience with the OKA-strain live varicellae vaccine. Postgrad Med J 1985; 61(Suppl 4): 113–20.
   PubMedGoogle Scholar
• Hall CB, Chesney PJ, Gromisch DS, Halsey NA, Kohl S, Marcy SM, et al. Recommendations for the use of live attenuated varicella vaccine. Committee on Infectious Diseases. Pediatrics 1995; 95: 791–6.
   Google Scholar
• Ross LF, Lantos JD. Immunisation against chickenpox. Better to confine immunisation to those at high risk. Br Med J 1995; 310: 2–3.
   Google Scholar
• Taylor JA. Herd immunity and the varicella vaccine. Is it a good thing? Arch Pediatr 2001; 155: 440–1.
   Google Scholar
• Fleisher G, Henry W, McSorley M, Arbeter A, Plotkin S. Life threatening complications of varicella. Am J Dis Child 1981; 135: 896–9.
   PubMedGoogle Scholar
• Anonymous. Varicella-related deaths – Florida, 1998. MMWR 1999; 48: 379–81.
   PubMedGoogle Scholar
• Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1995–7: analysis of routine mortality data. Br Med J 2001; 1091–3.
   Google Scholar
• Whitley RJ. Varicella-zoster virus. In: Mandell GL, Douglas RG, Benet JE, eds. Practice and principle of infectious diseases. New York: Churchill Livingstone; 1990. p. 1153–9.
   Google Scholar
• Ndumbe PM, Macqueen S, Holzel H, Levinsky RJ. Immunity to varicella-zoster virus in a normal adult population. J Med Microbiol 1985; 20: 105–11.
   PubMedGoogle Scholar
• Heininger U, Braun-Fahrlander C, Desgrandchamps D, Glaus J, Grize L, Wutzler P, Schaad UB. The SCARPOL Team. Seroprevalence of varicella-zoster virus immunoglobulin G antibodies in Swiss adolescents and risk factor analysis for seronegativity. Pediatr Infect Dis J 2001; 20: 775–8.
   PubMedGoogle Scholar
• Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine 2001; 10: 121–4.
   Google Scholar
• Paryani S, Arvin A. Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 1986; 314: 1542–6.
   PubMed Web of Science ®Google Scholar
• Katz VL, Kuller JA, McMahon MJ, Warren MA, Wells SR. Varicella during pregnancy. Maternal and fetal effects. West J Med 1995; 163: 446–50.
   Google Scholar
• Gershon AA, Steinberg S. NIAID Collaborative Varicella Vaccine Study Group. Live attenuated varicella vaccine: protection in healthy adults in comparison to leukemic children. J Infect Dis 1990; 161: 661–6.
   Google Scholar
• Nader S, Berger R, Sharp M, Arvin A. Age-related difference of cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 1995; 171: 13–7.
   PubMed Web of Science ®Google Scholar
• Steele RW, Coleman MA, Fiser M, Bradsher RW. Varicella zoster in hospital personnel: skin test reactivity to monitor susceptibility. Pediatrics 1982; 70: 604–8.
   PubMedGoogle Scholar
• Myers MG, Rasley DA, Hierholzer WJ. Hospital infection control for varicella zoster virus infection. Pediatrics 1982; 70: 199–202.
   Google Scholar
• Vandersmissen G, Moens G, Vranckx R, de Schryver A, Jacques P. Occupational risk of infection by varicella zoster virus in Belgian healthcare workers: a seroprevalence study. Occup Environ Med 2000; 57: 621–6.
   Google Scholar
• Anonymous. Socialstyrelsens allmänna råd (SOSFS 1996:1) om vaccination av barn. Stockholm: Socialstyrelsen; 1996. (In Swedish.)
   Google Scholar
• Saiman L, LaRussa P, Steinberg SP, Zhou J, Baron K, Whittier S, Della-Latta P, Gershon AA. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol 2001; 22: 279–83.
   PubMedGoogle Scholar
• Linde A, Granström M, Örvell C. Immunoglobulin class and immunoglobulin G subclass enzyme-linked immunosorbent assays compared with microneutralization assay for serodiagnosis of mumps infection and determination of immunity. J Clin Microbiol 1987; 9: 1653–8.
   Google Scholar
• Ljungman P, Wilczek H, Garthon G, Gustavsson A, Lundgren G, Lönnqvist B, et al. Long-term acyclovir prophylaxis in bone-marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1986; 1: 185–92.
   Google Scholar
• Ljungman P, Lonnqvist B, Garthon G, Ringden O, Sundqvist VA. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986; 155: 840–7.
   Google Scholar
• Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 1995; 20: 316–9.
   PubMed Web of Science ®Google Scholar
• Gershon AA. Varicella vaccine – are two doses better than one? N Engl J Med 2002; 347: 1962–3.
   PubMedGoogle Scholar
• Gallagher J, Quaid B, Cryan B. Susceptibility to varicella zoster virus in health care workers. Occup Med (Lond) 1996; 46: 289–92.
   Google Scholar
• Boulianne N, Duval B, De Serres G, Deceuninck G, Masse R, Couillard M. Most ten-year-old children with negative or unknown histories of chickenpox are immune. Pediatr Infect Dis J 2001; 20: 1087–8.
   PubMedGoogle Scholar
• Heininger U. Letter to the editor. Vaccine 2002; 20: 1480.
   PubMedGoogle Scholar
• Aebi C, Fischer K, Gorgievski M, Matter L, Mühlemann K. Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 2001; 19: 3097–103.
   Google Scholar
• Beutels P, Clara R, Tormans G, van Doorslaer E, van Damme P Cost and benefits of routine varicella vaccination in German children. J Infect Dis 1996; 174(Suppl 3): S335–41.
   PubMedGoogle Scholar
• Ross RT, Cheang M. Geographic similarities between varicella and multiple sclerosis: an hypothesis on the environmental factor of multiple sclerosis. J Clin Epidemiol 1995; 48: 731–7.
   PubMed Web of Science ®Google Scholar
• Mandal BK, Mukherjee PP, Murphy C, Mukherjee R, Naik T. Adult susceptibility to varicella in the tropics is a rural phenomenon due to lack of previous exposure. J Infect Dis 1998; 178(Suppl 1): S52–4.
   Google Scholar
• Parment PA, Insulander M. Mässlingsutbrott i Stockholms lan. Hygiea 2000; 109: 210. (In Swedish.)
   Google Scholar
• Broliden K, Rubilar Abreu E, Arneborn M, Böttinger M. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme. Vaccine 1998; 16: 323–7.
   Google Scholar
• Pipkin PA, Afsal MA, Heath AB, Minor PD. Assay of humoral immunity to mumps virus. J Virol Methods 1999; 79: 219–25.
   PubMed Web of Science ®Google Scholar
• Garcia Comas L, Ramirez R, Castaneda R, Sanz JC, Barranco D, Garcia J, Gutierrez MA. Seroprevalence of antibodies against mumps in the 2 to 5 year-old population of the autonomous region of Madrid and influence of the type of vaccine administered. In: 20th Annual Meeting European Society for Paediatric Infectious Diseases, Vilnius, 29–31 May 2002. p. 62.
   Google Scholar
• Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH Jr. Placebo-controlled trial of varicella vaccine given with or after measles–mumps–rubella vaccine. J Pediatr 1989; 114: 37–44.
   Google Scholar
• Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, Andre FE. Evaluation of live attenuated varicella vaccine (OKA-RIT strain) and combined varicella and MMR vaccination in 13–17-month-old children. Acta Paediatr Scand 1991; 80: 1051–7.
   PubMedGoogle Scholar
• Takayama N, Kidokoro M, Suzuki K, Morita M. (Immunization of healthy children with measles–mumps–rubella trivalent vaccine simultaneously given with varicella vaccine). Kansen-shogaku Zasshi 1992; 66: 776–80. (In Japanese.)
   PubMedGoogle Scholar
• Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella zoster vaccine (MMR(II)V) in healthy children. J Infect Dis 1996; 173: 731–4.
   PubMed Web of Science ®Google Scholar